News About: R&D
YD Life Science acquires approval of DR therapy for Phase 2a clinical trial in U.S.
YD Life Science(CEO Jin-Woo Lee) announced on the 21st that its diabetic retinopathy(DR) therapy ‘YD-312’ acquired final approval for a Phase 2a clinical trial from the U.S. Food and Drug Administration.
Diabetic ret...
ProteomeTech acquires approval of IgE content diagnostic kit for first time in Korea
ProteomeTech(CEO Kook-Jin Lim) announced sales and manufacturing approval of the real-time monitoring of human IgE content ‘ImmuneCheck IgE’ from the Ministry of Food and Drug Safety on 8 August.
‘ImmuneCheck IgE,’ a...
Qurient acquires U.S. approval of Phase II clinical trial for MDR TB therapy Telacebec
Qurient(CEO Ki-Yeon Nam) announced a beginning of a Phase II clinical to globally develop a multi-drug resistant(MDR) tuberculosis(TB) therapy on the 17th of July.
Qurient said the company will start the Phase II cli...
"In order to raise chances, the number of clinical trials enter Phase II must be raised"
A position that a country takes in the new drug development field is decided based on the structure of clinical trials. While most clinical trials in the U.S. are on Phase I and Phase II, most Korean pharmaceutical co...
Korea put up a great fight in global downtrend with clinical studies
The number of clinical studies has decreased in the world, but Korea has had a slower decrease compared to other countries, showing a good sign.
According to the data that the National Institutes of Health(NIH) had i...
“In North Korea, selling profitable drugs is the main goal of studying pharmacology”
Despite researchers interested in and studying pharmacology even in North Korea, they eventually are led to developing profitable drugs for no purpose of study without any benefit from the government, to purchase food...
‘Artificial Intelligence’ over hypothesis-driven study
An opinion was raised that development of new drugs must go towards AI, not the conventional hypothesis-driven studies.
At the ‘Artificial Intelligence, New Paradigm of New Drug Development’ seminar on the 7th, Profe...
Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial
They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm.
A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase ...
Government to impose disciplinary fine for falsely reporting adverse drug reactions in clinical trials
If an institute or organization is exposed for a false report of adverse drug reactions during a clinical trial, a disciplinary fine will be imposed.
In order to keep patients participating in clinical trials safe an...
Curatis starts 2a clinical trial of adult tuberculosis vaccine this January
Curatis, an immune vaccine and immunotherapy company, announced to conduct a Phase 2a clinical trial of tuberculosis preventive vaccine for adults at Yonsei University Severance Hospital this January. The company acqu...
